Related Experiment Video
Updated: Aug 24, 2025

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
Filgotinib for moderately to severely active ulcerative colitis
Alessandro Mannucci1,2, Ferdinando D'Amico1,2,3, Ahmad El Saadi2
1Gastroenterology and Gastrointestinal Endoscopy Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Filgotinib is an effective oral JAK1 inhibitor for ulcerative colitis (UC) treatment. This review summarizes its efficacy, safety, and tolerability, noting its suitability for various patient groups.
Area of Science:
- Pharmacology
- Gastroenterology
- Immunology
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Janus kinase (JAK) inhibitors represent a therapeutic advancement for UC.
- Filgotinib selectively inhibits JAK1, offering a targeted approach.
Approach:
- Systematic literature review of studies on filgotinib in moderate to severe UC.
- Databases searched include PubMed, Scopus, and Embase.
- Analysis focused on efficacy, safety, tolerability, and specific risks like zoster infection and venous thromboembolism.
Key Points:
- Filgotinib demonstrates significant efficacy and a favorable safety profile in UC patients.
- It is effective in both biologic-naïve and biologic-experienced populations.
- Oral administration and rapid action enhance its therapeutic utility.
Conclusions:
- Filgotinib is a valuable oral treatment option for moderate-to-severe active UC.
- Its efficacy and safety profile support its use across different patient subgroups.
- Consideration of risks such as zoster and VTE is important in clinical practice.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
07:06Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...